NICE Rejects BMS' Opdivo As Adult Kidney Cancer Treatment
Executive Summary
The UK HTA NICE in draft guidance has rejected Bristol-Myers Squibb Co.'s Opdivo (nivolumab) as a therapy for previously treated advanced renal cell carcinoma in adults, saying the PD-1 inhibitor doesn't offer value for money. It added that it should also not be made available to such patients through the government-funded Cancer Drugs Fund, for the same reasons.
You may also be interested in...
Opdivo Turned Down By NICE In Head And Neck Cancer
BMS looks unlikely to have a positive NICE opinion synchronized with European approval of Opdivo in head and neck cancer, after the HTA body turned down the checkpoint inhibitor in its draft appraisal.
NICE OK For BMS's Opdivo To Shake Up UK RCC Market, Bad News For Pfizer
Bristol-Myers Squibb's Opdivo looks set to blow rivals out the water in renal cell carcinoma as NICE U-turns on negative recommendation, just weeks after the company revealed the full extent of the drug’s disappointment in first-line lung cancer.
UK's NICE OKs BMS' Opdivo-Yervoy Combo In Advanced Skin Cancer
The UK HTA has recommended Bristol-Myers Squibb's combination therapy of Opdivo and Yervoy to treat patients on the publicly-funded NHS with advanced skin cancer, marking one of the quickest decisions ever from NICE and issued only weeks after the combo was licensed by the EU's European Commission.